A team of Harvard and Sloan Kettering scientists has developed compounds that can target and degrade proteins associated with acute myeloid leukemia (AML) and nearly doubled the life expectancy of mice with cancer in laboratory tests.

TFome technology, advanced through Blavatnik Biomedical Accelerator, may contribute to new cell therapies

Harvard’s ARMMs technology to be commercialized by Vesigen Therapeutics for targeted intracellular delivery of large-molecule drugs

Five Fellows will work with innovators across Harvard community, advance commercialization of life-science technologies